Related Experiment Video
Updated: Jan 14, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Recurrent Ischaemic Stroke in a Patient With Left Ventricular Thrombus Despite Apixaban: Successful Transition to
Mohd Imran Patel1, Sindhuja Kannan1, Riya M Jacob1
1Internal Medicine, Prince Charles Hospital, Merthyr Tydfyl, GBR.
Left ventricular (LV) thrombus is a well-recognised source of cardioembolic stroke, especially in patients with severely reduced LV ejection fraction (LVEF). Anticoagulation is the mainstay of therapy, but the optimal agent remains debated. We report the case of a 68-year-old man with an LV thrombus who suffered recurrent ischemic strokes while on apixaban, with magnetic resonance imaging (MRI) of the brain demonstrating acute infarcts in the left thalamocapsular and occipitotemporal regions. Following multidisciplinary team review, he was transitioned to warfarin with low-molecular-weight heparin (LMWH) bridging, after which he achieved therapeutic international normalised ratio (INR) stability and experienced no further clinically apparent embolic events. This case underscores the ongoing embolic risk associated with LV thrombus despite direct oral anticoagulant (DOAC) therapy, the importance of LMWH bridging when initiating warfarin, and the value of multidisciplinary management in optimising outcomes.
Left ventricular (LV) thrombus is a well-recognised source of cardioembolic stroke, especially in patients with severely reduced LV ejection fraction (LVEF). Anticoagulation is the mainstay of therapy, but the optimal agent remains debated. We report the case of a 68-year-old man with an LV thrombus who suffered recurrent ischemic strokes while on apixaban, with magnetic resonance imaging (MRI) of the brain demonstrating acute infarcts in the left thalamocapsular and occipitotemporal regions. Following multidisciplinary team review, he was transitioned to warfarin with low-molecular-weight heparin (LMWH) bridging, after which he achieved therapeutic international normalised ratio (INR) stability and experienced no further clinically apparent embolic events. This case underscores the ongoing embolic risk associated with LV thrombus despite direct oral anticoagulant (DOAC) therapy, the importance of LMWH bridging when initiating warfarin, and the value of multidisciplinary management in optimising outcomes.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management

